Educational and behavioral interventions hitherto published
|
|
- Alan Ross
- 5 years ago
- Views:
Transcription
1 Treatment of High-Risk Patients with Diabetes: Motivation and Teaching Intervention: A Randomized, Prospective 8-Year Follow-Up Study Rita Rachmani, Inna Slavacheski, Maya Berla, Ronni Frommer-Shapira, and Mordchai Ravid Department of Medicine, Sackler School of Medicine, Tel-Aviv University, and Meir Hospital, Kfar-Sava, Israel The aim of this study was to examine whether motivating patients to gain expertise and closely follow their risk parameters will attenuate the course of microvascular and cardiovascular sequelae of diabetes. A randomized, prospective study was conducted of 165 patients who had type 2 diabetes, hypertension, and hyperlipidemia and were referred for consultation to a diabetes clinic in an academic hospital. Patients were randomly allocated to standard consultation (SC) or to a patient participation (PP) program. Both groups were followed by their primary care physicians. The mean follow-up was 7.7 yr. The SC group attended eight annual consultations. The PP patients initiated on average one additional consultation per year. There were 80 cardiovascular events (eight deaths) in the SC group versus 47 events (five deaths) in the PP group (P 0.001). The relative risk (RR) over 8 yr for a cardiovascular event in the intervention (PP) versus the control (SC) group was 0.65 (95% confidence interval, 0.89 to 0.41). There were 17 and eight cases of stroke in the SC and PP groups, respectively (P 0.05). RR for stroke was 0.47 (95% confidence interval, 0.85 to 0.32). In the SC group, 14 patients developed overt nephropathy (four ESRD) versus seven (one ESRD) in the PP group (P 0.05). Throughout the study period, BP, LDL cholesterol, and hemoglobin A 1c were significantly lower in the PP than in the SC patients. Well informed and motivated patients were more successful in obtaining and maintaining good control of their risk factors, resulting in reduced cardiovascular risk and slower progression of microvascular disease. J Am Soc Nephrol 16: S22 S26, doi: /ASN Educational and behavioral interventions hitherto published in patients with diabetes had only modest effects on alleviation of disease progression (1). The poor outcomes may be partially due to deficiencies in diabetes knowledge, compliance, and motivation (2,3). Intensive therapeutic programs are effective in reducing diabetic complications and cardiovascular morbidity and mortality (4 9). These programs, however, all have been randomized, prospective trials conducted by experts in academic medical centers. The extrapolation of the achievements of these programs to primary care is difficult because of both financial and organizational shortcomings. We showed previously that sharing the therapeutic responsibility with the patients themselves had a major impact on retarding the progress of microvascular complications (10). Reported herein is the second, 4-yr, phase of the study highlighting the influence of the intervention on cardiovascular outcomes. Materials and Methods A total of 167 patients who had type 2 diabetes, hypertension, and dyslipidemia and referred for consultation to the diabetes clinic of Meir Hospital during the years 1995 to 1996 were randomized to a standard consultation (SC) or to a patient-participation program (PP). The inclusion criteria were age 40 to 70 yr; type 2 diabetes of 10 yr duration; BMI 35 kg/m 2 ; BP values 140/90 mmhg; LDL 120 mg/dl; serum Address correspondence to: Prof. M. Ravid, Maaynei-Hayeshua Medical Centre, Bnei Brack, Israel. Fax: ; ravidm@netvision.net.il creatinine 2 mg/dl (176 mol/l); albumin/creatinine ratio 200 mg/g; and no history of myocardial infarction, angina pectoris, vascular surgery, stroke, or any systemic or malignant disease. A total of 154 patients signed informed consent forms, 13 patients were excluded, and 141 were randomized by the help of computergenerated random numbers to either SC (n 70) or PP (n 71) programs. The flow of the patients throughout the study is outlined in Figure 1. Patients of both groups were initially interviewed and examined twice over 2 wk and annually thereafter. Consultation letters were written to the family physicians. No prescriptions were ever issued by members of the consultation team. The patients of the SC group attended standard consultation visits, whereas the patients of the PP program were given two 2-h teaching sessions about ways to achieve tight control of the modifiable risk factors including also an individualized plan of lifestyle modification and a fitness program, instructed to measure BP weekly, keep records of the results of the laboratory investigations, and urge their physicians to change or intensify treatment if the target values of BP (130/80 mmhg), LDL cholesterol (100 mg/dl), and hemoglobin A 1c (HbA 1c ) (7%) were not reached. These patients were encouraged to call the consultants when they believed that they needed advice. Sixty-five patients in the SC group and 64 in the PP group completed the first 4-yr phase. The follow-up was continued for an additional 4 yr, bringing the mean follow-up period to yr. Data on clinical outcome events were obtained from the letters of the primary care physicians, hospital discharge summaries, or other consultants reports. The protocol was approved by the institutional ethical committee. The hospital laboratory serves the whole area; all laboratory examinations therefore were done centrally. The assays were unchanged during the Copyright 2005 by the American Society of Nephrology ISSN: /
2 J Am Soc Nephrol 16: S22 S26, 2005 Teaching Diabetic Patients to Monitor Their Risk Factors S23 Statistical Analyses The power calculations and the ascertainment of adequate randomization were previously described (10). The primary end points for the first 4-yr analysis were the change in renal function as expressed by e-gfr and the change in albumin/creatinine ratio. For the 8-yr analysis, the primary end points were total mortality and the combined cardiovascular event index (cardiovascular mortality, nonfatal myocardial infarction [MI], nonfatal stroke, coronary bypass surgery, coronary angioplasty, amputation, or vascular surgery for peripheral atherosclerotic artery disease). Secondary end points were e-gfr and albumin/ creatinine ratio. The annual means of the various measurements were compared by ANOVA and by paired or unpaired t test. The renal outcome parameters were assessed by linear regression analysis. The analysis was done on an intention-to-treat basis. The last available data of participants who died or left the study were carried forward to be included in the final analysis. The detailed statistical methods were previously described (10). This study was carried out by the authors without external financial support. Figure 1. Flow of participants through the trial. study period. The analytical methods were previously described (10). Renal outcome was assessed by estimated GFR (e-gfr) (11). Results The baseline characteristics of the patients of the PP and SC groups were previously described (10) and are shown in the first column of Table 1. There was no difference in any of the baseline characteristics between the two groups. Over 8 yr, the patients of the PP group initiated 826 additional visits to the consultation clinic, an average of visits/patient per yr. The main reason given by the patients was a failure to meet one or more of the target values of the risk factors. The patients in the PP group were more likely to receive angiotensin-converting enzyme inhibitors or angiotensin II antagonists than those of the SC group. Also, all PP patients were prescribed lipid-lowering medication versus one half of the SC patients. Glucose-lowering regimens were not different in the two groups. The prescribed daily doses of most of antihypertensive agents and those of statins were higher in the PP than in Table 1. Initial, 4-yr, and 8-yr values of the main risk parameters and renal outcome measures a Variable Initial (n 141) 4yr (n 129) 8yr (n 111) SBP (mmhg) SC b b PP DBP (mmhg) SC b b PP LDL cholesterol (mg/dl) SC b b PP HbA 1c (%) SC b b PP e-gfr (ml/min per 1.73 m 2 ) SC group b b PP group Alb/Cr ratio (mg/g) SC group 39 (17 186) 58 (25 673) b 185 ( ) b PP group 41 (15 194) 39 (15 374) 84 ( ) a Data are mean SD. SBP, systolic BP; SC, standard consultation; PP, patient participation; DBP, diastolic BP; HbA 1c, hemoglobin A 1c ; e-gfr, estimated GFR; Alb/Cr, albumin/creatinine. b P 0.05 for PP group versus SC group.
3 S24 Journal of the American Society of Nephrology J Am Soc Nephrol 16: S22 S26, 2005 the SC patients. The data on drug treatment are summarized in Table 2. Modifiable Risk Parameters There was a decrease in all risk parameters in both groups; the values were significantly lower in the patients of the PP group. The differences in BP and LDL cholesterol values were highly significant, whereas those of BMI and HbA 1c were modest (Table 1). Nephropathy and Retinopathy The average annual decline in estimated e-gfr in the SC and the PP groups was and ml/min per 1.73 m 2, respectively (P 0.01). Overt nephropathy (albumin/creatinine ratio 300 mg/g) developed in 14 (22%) patients in the SC group versus 7 (12.5%) in the PP group (P 0.01). The numbers of patients who developed ESRD were four and one in the SC and PP groups, respectively. Retinopathy was found in 35 versus 21 patients in the SC and PP groups, respectively (P 0.03). The relative risk reduction of microvascular complications in the intervention (PP) versus the control (SC) group was 0.57 (95% confidence interval, 0.91 to 0.28). These data are listed in Table 1 and shown in Figure 2. No standard method to assess neuropathy was used. Cardiovascular Disease In the SC group 12 patients died, eight of cardiovascular causes (five MI, three strokes). Among the PP patients, there were nine deaths, five of which were cardiovascular (three MI, two strokes). The number of nonfatal cardiovascular events was 72 in 45 patients of the SC group versus 47 in 31 patients of the PP group. Together with the cardiovascular fatal events, the total number of cardiovascular events was 80 versus 52 (P 0.001). There were significantly fewer events of stroke in the PP than in the SC group (fatal nonfatal stroke, 8 in the PP versus 17 in the SC group; P 0.01). There were also fewer coronary artery events and interventions in the PP than in the SC patients (fatal nonfatal MI coronary artery bypass graft PCI, 56 versus 41; P 0.046). Also, the participants of the PP program had fewer amputations and bypass surgeries than their SC counterparts (3 versus 7). A Kaplan-Meier estimation of event-free survival in the SC and PP groups is shown in Figure 3. The relative risk reduction of the main cardiovascular parameters is outlined in Table 3. Discussion The patients with diabetes were provided with in-depth information about their disease, motivated to actively pursue Table 2. Drug treatment of the patients in the PP and SC groups, initially, after 4 yr, and at the end of the study a Initial 4 Yr 8 Yr (n 70) (n 71) (n 65) (n 64) (n 54) (n 56) Antihypertensive ACE-I or ARB 13 (19) 15 (21) 34 (54) 64 (100) b 40 (74) 56 (100) b HCTZ 4 (6) 4 (6) 24 (37) 62 (97) b 39 (72) 50 (89) b CCB 24 (34) 26 (37) 36 (55) b 15 (23) 31 (57) b 16 (29) -blockers 16 (23) 18 (25) 24 (37) 23 (36) 28 (52) 22 (39) -blockers 6 (9) 5 (7) 15 (23) 16 (25) 19 (33) 14 (25) Patients on drug 2 drugs drugs Lipid lowering statins 6 (9) 5 (7) 22 (34) 52 (81) b 32 (59) 54 (96) b fibrates 3 (4) 4 (6) 4 (6) 13 (20) b 4 (7) 0 statins and fibrates 2 (3) 10 (16) 4 (7) 2 (4) Glucose lowering diet alone 16 (23) 18 (25) 4 (6) 0 0 sulfonylurea 29 (41) 27 (38) 14 (28) 9 (14) b 10 (19) b 2 (4) metformin 7 (10) 9 (13) 6 (9) 12 (19) b 6 (11) 4 (7) sulfonylurea metformin 10 (14) 7 (10) 18 (28) 25 (38) 10 (19) 19 (34) glitazones 4 (7) 6 (11) insulin 8 (11) 10 (14) 23 (35) 18 (28) 24 (44) 25 (44) aspirin 21 (30) 23 (32) 37 (57) 60 (94) b 42 (78) 56 (100) b a Data are n (%). ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; HCTZ, hydrochlorothiazide; CCB, calcium channel blockers. b P 0.05 for the difference between PP and SC groups.
4 J Am Soc Nephrol 16: S22 S26, 2005 Teaching Diabetic Patients to Monitor Their Risk Factors S25 Figure 3. Kaplan-Meier estimation of combined cardiovascular event-free survival in SC and PP groups (P by the log-rank test). Cum survival, cumulative survival; GRP, group. Table 3. Relative risk reduction (95% CI) of the main cardiovascular parameters in the intervention (PP) versus the control (SC) groups a Parameter RR (95% CI) MI 0.79 ( ) Stroke 0.47 ( ) CABG PCI 0.70 ( ) Nonfatal CV events 0.65 ( ) CV mortality 0.62 ( ) Non-CV mortality 1.0 Figure 2. Mean values of estimated GFR (e-gfr; see Results) and albumin/creatinine ratio (ACR). Standard care (SC) and patient participation (PP) groups during 8 yr. a CI, confidence interval; MI, myocardial infarction; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; CV, cardiovascular. their therapeutic goals, and given tools to monitor their modifiable risk factors. This was achieved via individual teaching sessions and enabling contact between patients and consultants. During 8 yr of follow-up, the cardiovascular morbidity was significantly reduced in the PP versus the SC patients. The progress of microvascular disease expressed by the annual decline in e-gfr, the rise in albuminuria, and the number of patients with retinopathy was significantly retarded already after 4 yr; at 8 yr, this difference grew in favor of the PP group. The more favorable clinical outcome of the PP patients is borne out by the significantly lower values of the major risk parameters. Thus, the PP patients had lower BMI, lower systolic (7 mm) and diastolic (5 mm) BP, lower LDL (116 versus 128 mg/dl), and lower HbA 1c values (8.3 versus 9.2%). These differences may be partially accounted for by some differences in therapeutic policies. All PP patients received renin-angiotensin system blockers throughout the study period as compared with 54 and 74% of the patients in the SC group during 4 and 8 yr, respectively. All PP patients were on lipid-lowering medications as compared with only 34 to 59% of the SC patients at 4 and 8 yr. Furthermore, the average daily dose of angiotensinconverting enzyme inhibitors and statins was higher in the PP than in the SC patients. Also, more PP patients were on three antihypertensive drugs than their SC counterparts. The differences in glucose-lowering therapy between the groups were less conspicuous. The better compliance, perseverance, and strictness in recording personal data of the PP patients are, most probably, the main reasons for the lower values of the main risk factors in this group. The results of this study compare favorably with early as well as recently published intensive care interventions in high-risk patients with diabetes (4 9). Most randomized, controlled studies that have compared intensive and less intensive regimens (4,7,12 15) concentrated on a single intervention, lowering BP, lipids, or glucose. The favorable outcome of the intensive versus less intensive patient groups in such studies compares well with the results of similar
5 S26 Journal of the American Society of Nephrology J Am Soc Nephrol 16: S22 S26, 2005 studies that used multiple interventions (6,8 10). This similarity is probably due to better compliance of patients who participate in clinical trials also with other prescribed medications on top of the trial drug. Every intensive intervention has a dual effect: A direct effect of the trial intervention itself and an indirect, perhaps not less powerful, effect of improved general motivation and compliance. The present study isolates and highlights the indirect effect because there was no direct pharmaceutical intervention in either of the groups. The power of the patients to attenuate the clinical course of their disease stands out in view of failures of educational programs previously published (1,16 18). The difference lies perhaps in the availability of the contact with the consultants throughout the study period and the reinforcement of education and motivation of the patients during the repeated annual consultation sessions. References 1. Gary TL, Gentringer JM, Guallar E, Peyrot M, Brandcati FL: Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. Diabetes Educ 29: , Murata GH, Shah JH, Adam KD, Wendel CS, Bokhari SU, Sulvan PA, Hoffman RM, Dudkworth WC: Factors affecting diabetes knowledge in type 2 diabetic veterans. Diabetologia 46: , Alazvi MH, Neal RD: The association between satisfaction with services provided in primary care and outcomes in type 2 diabetes mellitus. Diabet Med 20: , UK Prospective Diabetes Study Group: Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS 33. Lancet 352: , UKPDS Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 317: , Sawicki PT, Mullhanser I, Didjurgeit M, Reimann M, Bender R, Berger M: Mortality and morbidity in treated hypertensive type 2 diabetic patients with micro or macroproteinuria. Diabet Med 12: , Hansson L, Zanchetti A, Julius S: Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 351: , Gaede P, Vedel P, Parving HH, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno Type 2 Randomized Study. Lancet 353: , Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: , Rachmani R, Levi Z, Slavachevski I, Avin M, Ravid M: Teaching patients to monitor their risk factors retards the progression of vascular complications in high-risk patients with type 2 diabetes mellitus A randomized prospective study. Diabet Med 19: , Levy AS, Bosch JP, Breyer Lewis J, Green T, Togers N, Toth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: , Pyorala K, Pedersen TR, Kjekshus J, Fargeman O, Olsson AC, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20: , Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: A 7-year follow-up study. Arch Intern Med 156: , The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342: , The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: , Kanters SDJM, Algra A, de Bruint TWA, Erkelens DM, Banga JD: Intensive lipid lowering strategy in patients with diabetes mellitus. Diabet Med 16: , Holt W, Johnson A, de Belder M: Patient empowerment in secondary prevention of coronary heart disease. Lancet 356: 314, White WB, Asmar R, Imai Y: Task force VI: Self-monitoring of the blood pressure. Blood Press Monit 4: , 1999
Prevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationAmerican Academy of Insurance Medicine
American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationCV Risk Management in Diabetes Mellitus
CV Risk Management in Diabetes Mellitus J R Minkoff MD, FACP Endocrinology Clinical Professor of Family and Community Medicine University of California, San Francisco Mr. B 40 y/o Latino male c/o fatigue,
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationDiabetes Control and Complications in Public Hospitals in Malaysia
ORIGINAL ARTICLE Diabetes Control and Complications in Public Hospitals in Malaysia Mafauzy M. FRCP For the Diabcare-Malaysia Study Group, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian,
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationDiabetes and kidney disease.
Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationAccording to the US Renal Data System,
DIABETIC NEPHROPATHY * Mohamed G. Atta, MD ABSTRACT *Based on a presentation given by Dr Atta at a CME dinner symposium for family physicians. Assistant Professor of Medicine, Division of Nephrology, Johns
More informationMicrovascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationIncreased Risk of Renal Deterioration Associated with Low e-gfr in Type 2 Diabetes Mellitus Only in Albuminuric Subjects
ORIGINAL ARTICLE Increased Risk of Renal Deterioration Associated with Low e-gfr in Type 2 Diabetes Mellitus Only in Albuminuric Subjects Shu Meguro, Toshikatsu Shigihara, Yusuke Kabeya, Masuomi Tomita
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationSupplementary Online Content
Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationThe target blood pressure in patients with diabetes is <130 mm Hg
Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationNew Treatment Options for Diabetic Nephropathy patients. Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland
New Treatment Options for Diabetic Nephropathy patients Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland Diabetes and nephropathy Diabetic nephropathy is the most common
More informationCardiovascular outcomes in type 2 diabetes: the impact of preventative therapies
Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Issue: The Year in Diabetes and Obesity Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies Sophia
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationCase study: Lean adult with no complications, newly diagnosed with type 2 diabetes
Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes Authored by Clifford Bailey and James LaSalle on behalf of the Global Partnership for Effective Diabetes Management. The
More informationDiabetes and Hypertension
Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee
More informationNew Antihypertensive Strategies to Improve Blood Pressure Control
New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationManagement of Cardiovascular Disease in Diabetes
Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western
More informationStatin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography
Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationIndiana Medicaid Drug Utilization Review Board Newsletter
Indiana Medicaid Drug Utilization Review Board Newsletter Volume 12 Issue 4 October 2009 Indiana Medicaid DUR Board Room W382 Indiana State Government Center, South 402 West Washington Street Indianapolis,
More informationUpdate on Diabetes. Ketan Dhatariya. Why it s Not Just About Glucose Lowering Any More. Consultant in Diabetes NNUH
Update on Diabetes Why it s Not Just About Glucose Lowering Any More Ketan Dhatariya Consultant in Diabetes NNUH The Story So Far.. DCCT Retinopathy Neuropathy Nephropathy Intensive glucose control in
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationComplications of Diabetes: Screening and Prevention
Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy
More informationRENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2
Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic
More informationRisk factors associated with the development of overt nephropathy in type 2 diabetes patients: A 12 years observational study
Indian J Med Res 136, July 2012, pp 46-53 Risk factors associated with the development of overt nephropathy in type 2 diabetes patients: A 12 years observational study Vijay Viswanathan, Priyanka Tilak
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationMRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled
Articles MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled trial Heart Protection Study Collaborative Group* Summary Background
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy
Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. All hypercholesterolaemic diabetics
More informationComplications of Diabetes: Screening and Prevention. Dr Martin McIntyre Consultant Physician Royal Alexandra Hospital Paisley
Complications of Diabetes: Screening and Prevention Dr Martin McIntyre Consultant Physician Royal Alexandra Hospital Paisley Diabetic Complications Microvascular: Retinopathy Nephropathy Neuropathy Macrovascular:
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationRenal Protection Staying on Target
Update Staying on Target James Barton, MD, FRCPC As presented at the University of Saskatchewan's Management of Diabetes & Its Complications (May 2004) Gwen s case Gwen, 49, asks you to take on her primary
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationDIABETES MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: DIABETES MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN DIABETES MEASURES GROUP: #1. Diabetes: Hemoglobin A1c Poor Control #2. Diabetes: Low Density Lipoprotein (LDL-C)
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationFirenze 22 settembre 2007
Istituto di di medicina dello sport di di Firenze AMES Prevenzione cardiovascolare e cambiamenti negli stili di vita Firenze 22 settembre 2007 Orientamenti attuali per un intervento farmacologico e non
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationIndividualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus
1 Dissertation Title Page: Individualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus Qian Shi, MPH, PhD candidate Department of Global Health Management
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationData Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial
Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial 1 Background This Data Analysis Plan describes the strategy, rationale and statistical methods
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationBlood pressure treatment target in diabetes. Should it be <130 mmhg?
Blood pressure treatment target in diabetes Should it be
More informationA Fork in the Road: Navigating Through New Terrain
A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationUpdates in Cardiovascular Recommendations for Diabetic Patients
Updates in Cardiovascular Recommendations for Diabetic Patients Chris Tawwater, Pharm.D., BCPS Clinical Pharmacist, Abilene Regional Medical Center Assistant Professor, Adult Medicine Division Pharmacotherapy
More informationACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence?
Reviews ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence? George L. Bakris, MD; 1 and Matthew Weir, MD 2 Although angiotensin-converting
More informationPrevention of Cardiovascular Disease
Save Thais from Heart Diseases 2019 Prevention of Cardiovascular Disease Orawan Anupraiwan, MD. Central Chest Institute of Thailand ASCVD Prevention Pyramid Risk categories Very high-risk High-risk Documented
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationAggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
More informationFive chapters 1. What is CVD prevention 2. Why is CVD prevention needed 3. Who needs CVD prevention 4. How is CVD prevention applied 5. Where should CVD prevention be offered Shorter, more adapted to clinical
More information